DefiniGEN and Atelerix Collaborate to Ship In Vitro Cell Models Internationally Without the Need for Freezing or Cryopreservation

CAMBRIDGE, England & NEWCASTLE, England–(BUSINESS WIRE)–DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix’s hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.


In vitro liver models are laboratory-created liver cells or tissues that mimic the natural behaviour of the liver in the human body. These models allow scientists to study liver functions and diseases while reducing the need to use live animals. Additionally, these models provide a controlled environment for testing the effects of drugs on the liver, supporting the development of safer and more effective medications. They can also speed up the drug development process, as researchers can quickly assess drug toxicity and metabolism information.

Samples are shipped fresh to customers in assay ready plates for screening and analysis, enhancing the quality of functional assays. This saves research time, as cells do not need to be thawed, and avoids the need for cold chain logistics.

Heidi Kingdon Jones, CBO of DefiniGEN, said: “By combining DefiniGEN’s innovative iPSC-derived hepatocyte models with Atelerix’s revolutionary preservation technology, we are not only pushing the boundaries of scientific research but also contributing to a more sustainable and ethical approach in the biopharmaceutical industry. This collaboration marks an industry first in R&D, enabling higher quality functional assays without the reliance on cold chain logistics.”

Alastair Carrington, CEO of Atelerix, added: “Our technology for shelf-stable science solutions has proven to be a game-changer in the field of biopreservation. This partnership demonstrates the efficacy of Atelerix’s preservation technology, exceeding expectations with what is deemed one of the most sensitive and often problematic cell types, to ship fresh and still maintain functionality. Working alongside DefiniGEN, we are excited to be at the forefront of reducing the industry’s carbon footprint, improving the logistics of biological materials while moving towards reducing or even replacing the use of animals in drug testing.”

Contacts

Media Enquiries:
Lorna Cuddon

Zyme Communications

Email: [email protected]
Tel: +44 (0) 7811 996 942

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.